Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102431 | 0.87 | GBA1 (0.42) | SMN1; SMN2ALDH1A1GBA1HTR6KMT2A | |
| SCHEMBL19234423 | 0.85 | HTR6 (0.45) | SMN1; SMN2ALDH1A1GBA1HTR6KMT2A | |
| SCHEMBL8272556 | 0.85 | HTR6 (0.55) | SMN1; SMN2ALDH1A1HTR6 | |
| SCHEMBL4743569 | 0.84 | GBA1 (0.59) | SMN1; SMN2ALDH1A1GBA1HTR6KMT2A | |
| SCHEMBL8272554 | 0.82 | MCOLN3 (0.44) | SMN1; SMN2ALDH1A1HTR6 | |
| SCHEMBL14282764 | 0.80 | KMT2A (0.58) | ALDH1A1GBA1HTR6KMT2AKDM4E | |
| SCHEMBL19234330 | 0.79 | HTR6 (0.48) | HTR6TSHRHTR2C | |
| SCHEMBL14375100 | 0.79 | SLC12A2 (0.52) | SMN1; SMN2ALDH1A1HTR6KMT2ATSHR | |
| SCHEMBL8288130 | 0.78 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KMT2AGAA | |
| SCHEMBL14102424 | 0.76 | HTR6 (0.51) | SMN1; SMN2ALDH1A1HTR6KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | SMN1; SMN2 4552/4885ALDH1A1 382/4885GBA1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.